



ABN: 97 084 464 193

Suite 1 A, Level 2
802 Pacific Highway
Gordon NSW 2072

P: +61 2 9844 5422
F: +61 2 9844 5445



ASX Announcement

21 January 2013

Update and Status review of HI-164 therapy for COPD

Bioxyne Limited (ASX: BXN) today announced it had taken possession of the individual patient database from the clinical study H-005 into the efficacy of its HI-164 therapy for chronic obstructive pulmonary disease (COPD).

Analysis of the full data-set has commenced, which will allow the Company to properly compare the information from Study H-005 with that of earlier studies. Preliminary status review is as follows:

- Study H-002/004 showed benefit in patients of all ages who produced sputum.
- Patients under 65 years of age showed benefit in both previous studies (H-002/004 and H-005).
- Patent life covering HI-164 is long dated. The active substance HI-164OV is covered to 2029.

Bioxyne now holds data on close to 500 patients with COPD ranging from mild to severe, and in seasons of moderate and low levels of bacterial infection.

BXN acknowledges the professional assistance that the clinical research specialists, Datapharm Australia, provided in carriage of the study HI-005. The insight they provided, especially in relation to patients under 65 years, has allowed the Company to plan for the future development of HI-164.

Future development could take a variety of forms and be in-house or external. Further announcement to the market will be made as the board considers the results more fully and develops the current strategic review.

For Further information please contact:

Dr Phillip Comans
Chief Executive Officer
Tel: +61 (0) 439-466-116

Tim Allerton or Andrew Geddes
CityPR
(02) 9267 4511

About Bioxyne

Bioxyne Limited (ASX:BXN) is an Australian immunotherapeutics business created in April 2012 through the reverse takeover of Probiomics (ASX: PCC) by privately held Hunter Immunology. The Company's lead therapy, HI-164OV is based on the Company's proprietary technology that uses the application of mucosal immunology to treat common human diseases. HI-164OV works by controlling bacterial infections of airways damaged by toxins. The global incidence of COPD, which includes common diseases like bronchitis and emphysema, is growing rapidly and is a substantial burden on health budgets. Bioxyne also makes and sells consumer food supplements, based on a proprietary probiotic compound, generating a source of revenues. For further information please visit www.bioxyne.com



ABN: 97 084 464 193

Suite 1 A, Level 2
802 Pacific Highway
Gordon NSW 2072

P: +61 2 9844 5422
F: +61 2 9844 5445



COPD

Chronic Obstructive Pulmonary Disease (COPD) is a disease largely caused by smoking but with a rising number of new cases caused by pollution in developing countries like China and India. The global demand for COPD treatments is growing rapidly with an analysis by the Australian Lung Foundation in 2008 indicating the wide economic cost of to the Australian economy in 2010 was estimated to be \$9 billion in direct and indirect costs, with \$1 billion incurred in direct health system expenditure. There are currently no effective treatments for COPD and 25 per cent of COPD patients admitted to hospital die within one year. Reducing hospital admissions is crucial and preventing exacerbations is the main choice of therapy.